Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease

Vicky M Avery, Frederick S Buckner, Jonathan Bayldon Baell, Alan H Fairlamb, Paul Michels, Rick L Tarleton

Research output: Contribution to journalLetterOther

Abstract

The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 neglected tropical diseases highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.
Original languageEnglish
Pages (from-to)1709 - 1718
Number of pages10
JournalFuture Medicinal Chemistry
Volume5
Issue number15
DOIs
Publication statusPublished - 2013

Cite this

Avery, Vicky M ; Buckner, Frederick S ; Baell, Jonathan Bayldon ; Fairlamb, Alan H ; Michels, Paul ; Tarleton, Rick L. / Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease. In: Future Medicinal Chemistry. 2013 ; Vol. 5, No. 15. pp. 1709 - 1718.
@article{9ae7f9ab00c64ae7bb7d653af3f195a8,
title = "Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease",
abstract = "The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 neglected tropical diseases highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.",
author = "Avery, {Vicky M} and Buckner, {Frederick S} and Baell, {Jonathan Bayldon} and Fairlamb, {Alan H} and Paul Michels and Tarleton, {Rick L}",
year = "2013",
doi = "10.4155/fmc.13.161",
language = "English",
volume = "5",
pages = "1709 -- 1718",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "15",

}

Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease. / Avery, Vicky M; Buckner, Frederick S; Baell, Jonathan Bayldon; Fairlamb, Alan H; Michels, Paul; Tarleton, Rick L.

In: Future Medicinal Chemistry, Vol. 5, No. 15, 2013, p. 1709 - 1718.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease

AU - Avery, Vicky M

AU - Buckner, Frederick S

AU - Baell, Jonathan Bayldon

AU - Fairlamb, Alan H

AU - Michels, Paul

AU - Tarleton, Rick L

PY - 2013

Y1 - 2013

N2 - The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 neglected tropical diseases highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.

AB - The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 neglected tropical diseases highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.

UR - http://www.future-science.com/doi/pdf/10.4155/fmc.13.161

U2 - 10.4155/fmc.13.161

DO - 10.4155/fmc.13.161

M3 - Letter

VL - 5

SP - 1709

EP - 1718

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 15

ER -